Idiopathic thrombocytopenic purpura

Česká verzia

Authors: L. Raida; A. Hluší; J. Procházková; J. Juráňová
Authors place of work: Přednosta: Prof. MUDr. Karel Indrák, DrSc. ; Fakultní nemocnice Olomouc ; Hemato-onkologická klinika ; Lékařská fakulta Univerzity Palackého, Olomouc
Published in the journal: Prakt. Lék. 2008; 88(12): 690-694
Category: Reviews

Summary

Idiopathic thrombocytopenic purpura (ITP) is a disease commonly seen by the haematologist. The incidence of ITP is 6 patients per 100 000 people a year. Children, usually suffering from the acute form of ITP, represent approximately half of these patients. On the other hand, the majority of adult patients require repeated therapeutic intervention because of recurrent chronic ITP associated with severe thrombocytopenia. It normally affects adults between 50 and 60 years of age. Many elderly patients have a significant comorbidity and their health status can be made worse with haematological treatment. Patients with active ITP accompanied with significant thrombocytopenia may often have to be referred back to various specialists to modify some diagnostic and therapeutic approaches.

Key words:
idiopathic thrombocytopenic purpura, corticosteroids, immunoglobulins, anti-D globulin, splenectomy, rituximab.

Zdroje

1. Ahn, Y.S., Rocha, R., Mylvaganam, R. et al. Long-term danazol therapy in autoimmune thrombocytopenia : unamaintaned remission and age-dependent response in women. Ann. Int. Med. 1989, 111, p. 723-729.

2. Braendstrup, P., Bjerrum, O.W., Nielsen, O.J., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am. J. Hematol. 2005, 78, p. 275-280.

3. Brighton, T.A., Evans, S., Castaldi, P.A. et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic puprpura and other immune thrombocytopenias. Blood 1996, 88, p. 194-201.

4. Bussel, J. Intravenous immunoglobulin therapy for the treatment of idiopathic thrombocytopenic purpura. Prog. Hemost. Thromb. 1986, 8, p. 103-125.

5. Cines, D.B., Bussel, J.B. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2004, 106, p. 2244-2251.

6. Cohen, Y.C., Djulbegovic, B., Shamai-Lubovitz, O. et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistently low platelets counts. Arch. Intern. Med. 2000, 160, p. 1630-1638.

7. Cooper, N., Stasi, R., Cunningham-Rundles, S. et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 2004, 125, p. 232-239.

8. Crow, A. R., Lazarus, A. H. Role of Fcg receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J. Pediatr. Hematol. Oncol. 2003, 25, p. 14-18.

9. Černá, M., Pospíšilová, D. Trombocytopenie. In Indrák, K. a kol. Hematologie. Praha/Kroměříž: Triton, 2006, s. 101-106.

10. Figueroa, M., Gehlsen, J., Hammond, D. et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N. Engl. J. Med. 1993, 328, p. 1226-1229.

11. Frederiksen, H., Schmidt, K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999, 94, p. 909-913.

12. George, J.N., Woolf, S.H., Raskob, E. et al. Idiopathic thrombocytopenic purpura: a practice guideline developer by explicit methods for the American Society of Hematology. Blood 1996, 88, p. 3-40.

13. George, J.N., Kojouri, K., Perdue, J.J. et al. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin. Hematol. 2000, 37, p. 290-298.

14. Gill, K.K., Kelton, J.G. Management of idiopathic thrombocytopenic purpura in pregnancy. Semin. Hematol. 2000, 37, p. 275-289.

15. Kiefel, V., Santoso, S., Weisheit, M. et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987, 70, p. 1722-1726.

16. Kojouri, K., Vesely, S.K., Terrell, D.R. et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, rediction of response, and surgical complications. Blood 2004, 104, p. 2623-2634.

17. Kuhne, T., Imbach, P., Bolton-Maggs, P.H.B. et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001, 358, p. 2122-2125.

18. McMillan, R., Wang, L., Tomer, A. et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2003, 103, p. 1364-1369.

19. McMillan, R., Wang, L., Tani, P. et al. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J. Thromb. Haemost. 2003, 1, p. 485-491.

20. Olsson, B., Andersson, P-O., Jernas, M. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Med. 2003, 9, p. 1123-1124.

21. Rudowski, W.J. Accessory spleens: clinical significance with particular reference to the recurence of idiopathic thrombocytopenic purpura. World J. Surg. 1985, 9, p. 422-430.

22. Scaradavou, A., Woo, B., Woloski, B.M.R. et al. Intravenous anti-D treatment of immune thrombocytopenic puprura: experience in 272 patients. Blood 1997, 89, p. 2689-2700.

23. Vidarsson, B., Önundarson, P.T. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb. Haemost. 2000, 83, p. 634-635.